DBV Technologies (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
DBVT has been the topic of several other reports. BidaskClub lowered shares of DBV Technologies from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 6th. Societe Generale lowered shares of DBV Technologies from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. JMP Securities began coverage on shares of DBV Technologies in a research note on Friday, November 17th. They issued an “outperform” rating on the stock. Jefferies Group reiterated a “buy” rating on shares of DBV Technologies in a research note on Thursday, August 31st. Finally, Barclays lowered their price target on shares of DBV Technologies from $58.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $49.63.
Several institutional investors have recently added to or reduced their stakes in DBVT. Janus Henderson Group PLC acquired a new position in shares of DBV Technologies during the 2nd quarter worth about $90,724,000. Citadel Advisors LLC acquired a new position in shares of DBV Technologies during the 3rd quarter worth about $7,794,000. Point72 Asset Management L.P. acquired a new position in shares of DBV Technologies during the 3rd quarter worth about $2,190,000. Sectoral Asset Management Inc increased its stake in shares of DBV Technologies by 34.2% during the 2nd quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock worth $6,398,000 after purchasing an additional 45,653 shares during the last quarter. Finally, Granite Point Capital Management L.P. acquired a new position in shares of DBV Technologies during the 3rd quarter worth about $1,698,000. Institutional investors own 46.92% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/27/dbv-technologies-dbvt-rating-lowered-to-sell-at-zacks-investment-research.html.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
What are top analysts saying about DBV Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DBV Technologies and related companies.